Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of therapeutic hepatitis B vaccine sequentially administered with entecavir in chronic hepatitis B
CTR20210513Phase 3Active
- Sponsor
- Jiangsu Mendel Gene Technology
- Start
- Apr 2021
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of εPA44, entecavir in Chronic Hepatitis B (CHB), sponsored by Jiangsu Mendel Gene Technology. Started Apr 2021; status: active.
02
Drugs
εPA44entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20210513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210513.